博客

免疫球蛋白

静脉注射免疫球蛋白(IVIG)的作用机制:详细解析

Nurse helping patient receiving IVIG at home

IVIG works through multiple pathways rather than a single mechanism. These mechanisms include suppression of specialized white blood cells, neutralization of autoantibodies, and regulation of immune responses. 

获得 IVIG 共同支付援助

(877) 778-0318

IVIG 是什么?

静脉注射免疫球蛋白(IVIG) is a blood product administered through an intravenous (IV) infusion. It contains purified antibodies obtained from the pooled plasma of healthy donors. 

When a foreign substance enters your body, your immune system produces protective proteins called antibodies or immunoglobulins (Ig). These antibodies attach to the foreign invader and eliminate it from the body. 

有五个 types of antibodies: IgA, IgD, IgE, IgG, and IgM. IVIG products mainly contain IgG antibodies (over 90% of the total). 

Your healthcare provider may prescribe IVIG to boost the immune system, treat autoimmune conditions, and prevent infections in individuals with weakened immune systems. 

IVIG Mechanism of Action

IVIG is not a single-target therapy; its effects vary depending on dose, disease, and patient factors.

For example, IVIG acts as a replacement therapy in individuals with antibody deficiencies. Also, it acts as an immunomodulator and an anti-inflammatory in many autoimmune and inflammatory disorders. 

Moreover, IVIG can be both pro-inflammatory and anti-inflammatory, depending on the dose. 

IVIG Mechanisms of Action in Immunodeficiencies

As a replacement therapy, IVIG primarily acts by replacing the deficient IgG. This helps neutralize pathogens and reduce recurrent infections.

For this purpose, the typical replacement dose is 200 mg/kg to 400 mg/kg body weight, administered every 3 weeks [1].

At low doses, IVIG interacts with the foreign invaders to help activate the first line of immune defense. This part of the immune system (also known as the complement system):

  • Targets the foreign substance, such as bacteria
  • Triggers inflammation to prevent infection
  • Eliminates the foreign substance from the body

So, low-dose IVIG usually promotes inflammation to protect your body from foreign organisms [2].

获得 IVIG 事先授权

安排咨询

IVIG Mechanism of Action in Autoimmune and Inflammatory Diseases

IVIG nurse standing next to a pole  set up with an IVIG bottle and a pump

IVIG can simultaneously interact with different components of the immune system. Thus, the immunomodulatory actions of IVIG involve multiple mechanisms and vary widely among diseases. 

High doses, usually 2 g/kg/month, are used in autoimmune and inflammatory diseases. Unlike replacement IVIG, high-dose IVIG is more immunosuppressive and anti-inflammatory [3]. 

The immunomodulatory effects of IVIG are thought to occur as a result of the following interactions [4,5,6,7,8]:

Interaction With Specific Blood Cells

Monocytes and macrophages are white blood cells that identify and remove pathogens from the body. They do so by releasing inflammatory substances and engulfing pathogens. In a healthy individual, the lifespan of these cells is tightly regulated to prevent excessive inflammation.  

However, in chronic inflammatory diseases, these cells survive for longer than usual. Consequently, their accumulation further increases inflammation. IVIG binds to these cells and helps reduce inflammation. 

IVIG may help reduce inflammation by suppressing T cell multiplication. T cells are white blood cells that fight off disease-causing microorganisms. 

According to a 2024 study, T cells that migrate from the periphery to the site of tissue injury are involved in the development of many chronic inflammatory disorders, including [9]:

IVIG can enhance or block the activity of natural killer cells (NK cells). NK cells are white blood cells that kill virally infected cells and cancer cells. IVIG blocks NK cell activity in women experiencing recurrent spontaneous abortions, leading to favorable pregnancy outcomes. 

Contrarily, IVIG enhances NK activity in Kawasaki disease and seizure disorders. 

Interaction With Autoantibodies

Autoantibodies are proteins made by the immune system. They attack the body’s healthy tissues instead of foreign substances. In some individuals, they can lead to the development of autoimmune disorders. 

IVIG neutralizes the pathogenic autoantibodies. By doing this, it prevents the immune system from attacking the body’s healthy tissues and organs. IVIG reduces the production of autoantibodies by blocking the expansion of B cells. 

IVIG is used in many autoimmune disorders, such as: 

与专家交谈

关于共付额援助
(877) 778-0318

常见问题

What is the mechanism of action of IVIG?

IVIG mechanisms of action vary widely depending on the dose, disease being treated, and patient factors. As a replacement therapy, IVIG works by replacing the missing antibodies in individuals with immunodeficiencies. As an immunomodulator, IVIG affects various immune cells and steps involved in immune regulation. 

What are IgM, IgG, IgA, IgD, and IgE?

They are five major types of immunoglobulins (antibodies). The subclasses of IgG and IgA are IgG1, IgG2, IgG3, IgG4, and IgA1 and IgA2, respectively. 

How does IVIG work to increase platelets?

Though the exact mechanism is unclear, IVIG may:

  • Reduce platelet destruction
  • Enhance signals for platelet production

How does IVIG work for Guillain-Barre syndrome?

Researchers have yet to determine the exact mechanism of action. However, they think IVIG can work for Guillain-Barre syndrome (GBS) by decreasing the pathogenic antibodies that attack the nerve cells. 

How does IVIG work in autoimmune disease? 

IVIG can help prevent tissue/organ damage in autoimmune disease by neutralizing the harmful antibodies and reducing the production of antibodies by B cells. 

How does IVIG help with myasthenia gravis?

The exact mechanism is not entirely understood. However, IVIG can help improve myasthenia gravis (MG) symptoms and muscle strength by neutralizing autoantibodies that impair communication between muscles and nerves.

参考:

  1. Jolles, S et al. “Clinical uses of intravenous immunoglobulin.” Clinical and experimental immunology vol. 142,1 (2005): 1-11. doi:10.1111/j.1365-2249.2005.02834.x
  2. A Durandy, S V Kaveri, T W Kuijpers, M Basta, S Miescher, J V Ravetch, R Rieben, Intravenous immunoglobulins – understanding properties and mechanisms, Clinical and Experimental Immunology, Volume 158, Issue Supplement_1, December 2009, Pages 2–13, https://doi.org/10.1111/j.1365-2249.2009.04022.x 
  3. Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG) [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554446/ 
  4. Patil, V. and Kaveri, S.V. (2013), The mechanisms of action of IVIG in autoimmune and inflammatory diseases. VOXS, 8: 185-188. https://doi.org/10.1111/voxs.12037 
  5. Burns, Jane C, and Alessandra Franco. “The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.” Expert review of clinical immunology vol. 11,7 (2015): 819-25. doi:10.1586/1744666X.2015.1044980 
  6. Shock, Anthony, et al. “Dissecting the Mechanism of Action of Intravenous Immunoglobulin in Human Autoimmune Disease: Lessons From Therapeutic Modalities Targeting Fcγ Receptors.” Journal of Allergy and Clinical Immunology, vol. 146, no. 3, July 2020, pp. 492–500, doi:10.1016/j.jaci.2020.06.036. 
  7. Parihar, Arti et al. “Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death.” Journal of innate immunity vol. 2,3 (2010): 204-15. doi:10.1159/000296507 
  8. Velikova, Tsvetelina et al. “Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine.” Antibodies (Basel, Switzerland) vol. 12,1 20. 2 Mar. 2023, doi:10.3390/antib12010020 
  9. Giovenzana, Anna, et al. “T Cell Trafficking in Human Chronic Inflammatory Diseases.” iScience, vol. 27, no. 8, July 2024, p. 110528, doi:10.1016/j.isci.2024.110528.
此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
Portrait of Saba R., a pharmacist sharing her experience with specialty treatment.
医学审核人 Saba Rassouli 博士,药学博士

Saba Rassouli 博士,药学博士,在伊朗出生长大。她于2022年以优异成绩毕业于马歇尔·B·凯彻姆大学,获得药学学位。工作中最让她感到满足的部分是能够像家人一样照顾每一位患者,并听到他们对AmeriPharma提供的服务感到满意和高兴。闲暇时,她喜欢散步、读书,以及品尝不同的餐厅和美食。

联系我们

如果您有兴趣与专家交谈或希望了解经济援助机会,请使用下面的联系表格与我们联系。.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知